Alteration of the Gut Microbiome in Inflammatory Bowel Disease
- PMID: 35901721
- DOI: 10.1159/000525925
Alteration of the Gut Microbiome in Inflammatory Bowel Disease
Abstract
Background: Alteration of the gut microbial structure and function (dysbiosis) is associated with the pathogenesis of various disorders including inflammatory bowel disease (IBD).
Summary: Under normal conditions, β-oxidation of butyrate consumes oxygen in colonocytes and maintains the anaerobic environment in the lumen. Depletion of butyrate-producing bacteria results in anaerobic glycolysis in colonocytes and increases oxygen diffusion into the lumen, leading to a luminal facultative anaerobe expansion. Dysbiosis in IBD is characterized by the reduced abundance of the phylum Firmicutes (e.g., Faecalibacterium, Roseburia, and Ruminococcus) and an increase of the phylum Proteobacteria (e.g., Enterobacteriaceae). The overall structure of the gut mycobiome differs markedly in IBD patients, particularly Crohn's disease (CD), compared with healthy individuals. An increase in the genus Candida is a major contributory factor in the alteration of the mycobiome in Japanese CD patients, but an increase in the genus Saccharomyces is characteristic in Western patients. The gut virome, which is mainly composed of bacteriophages (phages), influences gut homeostasis and pathogenic conditions via an interaction with the gut bacterial community. Alterations in the gut virome have been suggested in patients with IBD. This may alter either the immunogenicity of bacteria, thus affecting the bacteria-host interactions, or the bacterial functions such as antibiotic resistance and toxin synthesis.
Key message: Advances in DNA sequencing technology and bioinformatics have revolutionized our understanding of the microbiome in the gut.
Keywords: Butyrate; Mycobiome; Short-chain fatty acids; Virome.
© 2022 The Author(s). Published by S. Karger AG, Basel.
Similar articles
-
Reduced Abundance of Butyrate-Producing Bacteria Species in the Fecal Microbial Community in Crohn's Disease.Digestion. 2016;93(1):59-65. doi: 10.1159/000441768. Epub 2016 Jan 14. Digestion. 2016. PMID: 26789999
-
Features of the gut prokaryotic virome of Japanese patients with Crohn's disease.J Gastroenterol. 2022 Aug;57(8):559-570. doi: 10.1007/s00535-022-01882-8. Epub 2022 Jun 11. J Gastroenterol. 2022. PMID: 35689701
-
The Roles of Inflammation, Nutrient Availability and the Commensal Microbiota in Enteric Pathogen Infection.Microbiol Spectr. 2015 Jun;3(3). doi: 10.1128/microbiolspec.MBP-0008-2014. Microbiol Spectr. 2015. PMID: 26185088
-
A comprehensive guide to assess gut mycobiome and its role in pathogenesis and treatment of inflammatory bowel disease.Indian J Gastroenterol. 2024 Feb;43(1):112-128. doi: 10.1007/s12664-023-01510-0. Epub 2024 Feb 27. Indian J Gastroenterol. 2024. PMID: 38409485 Review.
-
Gut mycobiome: The probable determinative role of fungi in IBD patients.Mycoses. 2021 May;64(5):468-476. doi: 10.1111/myc.13238. Epub 2021 Feb 3. Mycoses. 2021. PMID: 33421192 Review.
Cited by
-
The transition from genomics to phenomics in personalized population health.Nat Rev Genet. 2024 Apr;25(4):286-302. doi: 10.1038/s41576-023-00674-x. Epub 2023 Dec 13. Nat Rev Genet. 2024. PMID: 38093095 Review.
-
Fungi in the Gut Microbiota: Interactions, Homeostasis, and Host Physiology.Microorganisms. 2025 Jan 2;13(1):70. doi: 10.3390/microorganisms13010070. Microorganisms. 2025. PMID: 39858841 Free PMC article. Review.
-
Exploration of the core pathway of inflammatory bowel disease complicated with metabolic fatty liver and two-sample Mendelian randomization study of the causal relationships behind the disease.Front Immunol. 2024 Apr 18;15:1375654. doi: 10.3389/fimmu.2024.1375654. eCollection 2024. Front Immunol. 2024. PMID: 38698841 Free PMC article.
-
Delivery Strategies of Probiotics from Nano- and Microparticles: Trends in the Treatment of Inflammatory Bowel Disease-An Overview.Pharmaceutics. 2023 Nov 8;15(11):2600. doi: 10.3390/pharmaceutics15112600. Pharmaceutics. 2023. PMID: 38004578 Free PMC article. Review.
-
Impact of Obesity on the Course of Management of Inflammatory Bowel Disease-A Review.Nutrients. 2022 Sep 25;14(19):3983. doi: 10.3390/nu14193983. Nutrients. 2022. PMID: 36235636 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical